Biotechnology - OncoMed Pharmaceuticals, Biotechnology

Filter

Popular Filters

FDA lifts partial clinical hold for OncoMed’s vantictumab trials

FDA lifts partial clinical hold for OncoMed’s vantictumab trials

29-08-2014

US biotech firm OncoMed Pharmaceuticals saw its shares leap 9.9% to $21.58 on Thursday on news that the…

BiotechnologyChief medical officerOncologyOncoMed PharmaceuticalsResearchRevised trial protocolsRevised trial protocolsUnited StatesUSAvantictumab

OncoMed CEO presses for better environment for biopharma innovation, at House hearings

13-12-2013

The case for encouraging biopharma innovation was presented yesterday at the US House Committee on Oversight…

BiotechnologyNorth AmericaOncoMed PharmaceuticalsPoliticsRegulationResearch

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Back to top